Lista de obras -

A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura ⬇️

artículo científico publicado el 2 de junio de 2011

A proposal: the need for thrombotic thrombocytopenic purpura Specialist Centres--providing better outcomes

artículo científico publicado en 2015

A single-center prospective study on the safety of plasma exchange procedures using a double-viral-inactivated and prion-reduced solvent/detergent fresh-frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy.

artículo científico publicado en 2016

Acquired, noncongenital thrombotic thrombocytopenic purpura in children and adolescents: clinical management and the use of ADAMTS 13 assays

artículo científico publicado en 2010

Atypical haemolytic uraemic syndrome in the eculizumab era: presentation, response to treatment and evaluation of an eculizumab withdrawal strategy

scientific article published on 27 March 2019

Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura

artículo científico publicado en 2016

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

artículo científico publicado en 2016

Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpura

scientific article published on 22 October 2020

Clinical outcomes and risk factors for severe COVID-19 infection in patients with haematological disorders receiving chemo- or immunotherapy

artículo científico publicado en 2020

Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune-mediated thrombotic thrombocytopenic purpura

scientific article published on 28 March 2019

Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura

artículo científico publicado en 2013

Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies

artículo científico publicado en 2013

Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura

artículo científico publicado en 2011

Expert statements on the standard of care in critically ill adult patients with atypical haemolytic uraemic syndrome

artículo científico publicado en 2017

Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies

artículo científico publicado en 2012

How I treat disseminated intravascular coagulation

artículo científico publicado en 2017

How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome

artículo científico publicado en 2014

How we manage haemostasis during sepsis

artículo científico publicado en 2019

How we manage patients with heparin induced thrombocytopenia

artículo científico publicado en 2016

How we manage thrombotic microangiopathies in pregnancy

artículo científico publicado en 2016

Human immunodeficiency virus associated thrombotic thrombocytopenic purpura--favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy

artículo científico publicado en 2011

Inhibitory anti-ADAMTS 13 antibodies: measurement and clinical application

artículo científico publicado en 2009

Isolated bone marrow involvement in diffuse large B cell lymphoma: a report of three cases with review of morphological, immunophenotypic and cytogenetic findings

artículo científico publicado en 2004

Management of thrombotic thrombocytopenic purpura: current perspectives

artículo científico publicado en 2014

Multiple centre evaluation study of ADAMTS13 activity and inhibitor assays.

artículo científico publicado en 2017

Mycophenolate mofetil therapy for severe immune thrombocytopenia

artículo científico publicado en 2015

Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.

artículo científico publicado en 2015

Plasma exchange for COVID-19 thrombo-inflammatory disease

artículo científico publicado en 2020

Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura

artículo científico publicado en 2017

Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura

artículo científico publicado en 2017

Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features

artículo científico publicado en 2008

Relationship between ADAMTS13 activity, von Willebrand factor antigen levels and platelet function in the early and late phases after TIA or ischaemic stroke.

artículo científico publicado en 2014

Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.

artículo científico publicado en 2007

Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura

artículo científico publicado en 2012

Response to 'Impact of immunosuppression on mortality in critically ill COVID-19 patients'

artículo científico publicado en 2020

Rituximab in the treatment of TTP ⬇️

artículo científico publicado el 1 de abril de 2012

Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura

artículo científico publicado en 2006

The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura

artículo científico publicado en 2007

The role of complement activation in COPD exacerbation recovery

artículo científico publicado en 2016

The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpura

artículo científico publicado en 2006

The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry

artículo científico publicado en 2015

Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond

artículo científico publicado en 2017

Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome Microangiopathy in Pregnancy

artículo científico publicado en 2016

Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes

artículo científico publicado en 2014

Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies

artículo científico publicado en 2013

Trends in the diagnosis and management of TTP: European perspective

artículo científico publicado en 2014

Lista de obras de

A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura ⬇️

A proposal: the need for thrombotic thrombocytopenic purpura Specialist Centres--providing better outcomes

A single-center prospective study on the safety of plasma exchange procedures using a double-viral-inactivated and prion-reduced solvent/detergent fresh-frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy.

Acquired, noncongenital thrombotic thrombocytopenic purpura in children and adolescents: clinical management and the use of ADAMTS 13 assays

Atypical haemolytic uraemic syndrome in the eculizumab era: presentation, response to treatment and evaluation of an eculizumab withdrawal strategy

Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpura

Clinical outcomes and risk factors for severe COVID-19 infection in patients with haematological disorders receiving chemo- or immunotherapy

Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune-mediated thrombotic thrombocytopenic purpura

Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura

Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies

Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura

Expert statements on the standard of care in critically ill adult patients with atypical haemolytic uraemic syndrome

Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies

How I treat disseminated intravascular coagulation

How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome

How we manage haemostasis during sepsis

How we manage patients with heparin induced thrombocytopenia

How we manage thrombotic microangiopathies in pregnancy

Human immunodeficiency virus associated thrombotic thrombocytopenic purpura--favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy

Inhibitory anti-ADAMTS 13 antibodies: measurement and clinical application

Isolated bone marrow involvement in diffuse large B cell lymphoma: a report of three cases with review of morphological, immunophenotypic and cytogenetic findings

Management of thrombotic thrombocytopenic purpura: current perspectives

Multiple centre evaluation study of ADAMTS13 activity and inhibitor assays.

Mycophenolate mofetil therapy for severe immune thrombocytopenia

Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.

Plasma exchange for COVID-19 thrombo-inflammatory disease

Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura

Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura

Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features

Relationship between ADAMTS13 activity, von Willebrand factor antigen levels and platelet function in the early and late phases after TIA or ischaemic stroke.

Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.

Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura

Response to 'Impact of immunosuppression on mortality in critically ill COVID-19 patients'

Rituximab in the treatment of TTP ⬇️

Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura

The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura

The role of complement activation in COPD exacerbation recovery

The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpura

The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry

Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond

Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome Microangiopathy in Pregnancy

Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes

Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies

Trends in the diagnosis and management of TTP: European perspective